Altinicline (SIB-1508Y, SIB-1765F) is a drug that acts as an agonist in nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. [2] It stimulates the release of dopamine and acetylcholine in the brain in both rodent and primate models, [3] and progressed to Phase II clinical trials for Parkinson’s disease , [4] where “non-antiparkinsonian or cognition enhancement, the effects have been demonstrated,” although its current state is unclear.

Leave a Comment

Your email address will not be published. Required fields are marked *